Hepcinat Plus

Daclatasvir 60 mg + Sofosbuvir 400 mg Tablets

Description: Daclatasvir 60 mg + Sofosbuvir 400 mg tablets are a combination antiviral medication used to treat chronic hepatitis C virus (HCV) infection. This fixed-dose combination targets different stages of the HCV life cycle to enhance treatment efficacy and simplify the treatment regimen.

Salt Composition:

• Daclatasvir: A direct-acting antiviral that inhibits the HCV NS5A protein, crucial for viral replication and assembly.
• Sofosbuvir: A nucleotide analog that inhibits the HCV NS5B polymerase, essential for viral RNA replication.

Key Features:

• Dual Action: Combines two potent antivirals for comprehensive HCV treatment.
• Convenient Dosing: Typically administered as a single daily tablet.
• Broad Efficacy: Effective against multiple HCV genotypes.

Benefits:

• Effective Treatment: High rates of sustained viral response (SVR) in clinical studies.
• Simplified Regimen: Fixed-dose combination makes adherence easier.
• Liver Health: Reduces viral load, inflammation, and fibrosis.

American Brand Names:

• Daklinza (Daclatasvir)
• Sovaldi (Sofosbuvir)

Indian Brand Names:

• Daclahep (Hetero)
• Dacla (Mylan)
• Sofodac (Zydus)
• Dacla-Sof (Various local brands)

Related Keywords: Daclatasvir 60 mg + Sofosbuvir 400 mg tablets, hepatitis C treatment, HCV combination therapy, antiviral medication, direct-acting antivirals, HCV NS5A inhibitor, HCV NS5B polymerase inhibitor, sustained viral response, liver health improvement.